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Adoptive cell therapy (ACT) for cancer, in 
which T cells are extracted from a cancer pa-
tient, expanded ex vivo, and readministered to 
the same patient, is increasingly the subject of 
clinical trials and has produced promising re-
sults, especially in cases where either surgery or 
chemotherapy failed to clear the tumor or its 
metastases (Gattinoni et al., 2006). The most 
remarkable results thus far have been produced 
in clinical trials of ACT for metastatic mela-
noma and the combination of surgery and ACT 
for hepatocellular carcinoma (June, 2007).
Current ACT protocols typically consist of 
isolating tumor-infiltrating lymphocytes (TILs) 
or peripheral CD8+ T cells from the patient 
before expanding the cells ex vivo, by either 
anti-CD3 mAb or peptide stimulation in the 
presence of IL-2, and then reinjecting them into 
the patient (Gattinoni et al., 2006). However, 
the efficacy of this approach is limited by sev-
eral possible factors: lack of specificity of the 
transferred T cells, immune suppression of CD8+ 
T cell effector activity, and insufficient recruit-
ment of the transferred T cells to the tumor site.
The ability of the transferred CD8+ cyto-
toxic T cells (CTLs) to recognize tumor anti-
gens is an essential requirement for the efficacy 
of ACT. When peripheral CD8+ T cells are 
harvested from patients, their antigen specific-
ity may be irrelevant to tumor recognition. 
A solution that has been proposed, and which 
is currently the focus of extensive research 
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Tumor-promoted constraints negatively affect cytotoxic T lymphocyte (CTL) trafficking to 
the tumor core and, as a result, inhibit tumor killing. The production of reactive nitrogen 
species (RNS) within the tumor microenvironment has been reported in mouse and human 
cancers. We describe a novel RNS-dependent posttranslational modification of chemokines 
that has a profound impact on leukocyte recruitment to mouse and human tumors. Intra-
tumoral RNS production induces CCL2 chemokine nitration and hinders T cell infiltration, 
resulting in the trapping of tumor-specific T cells in the stroma that surrounds cancer cells. 
Preconditioning of the tumor microenvironment with novel drugs that inhibit CCL2 modifi-
cation facilitates CTL invasion of the tumor, suggesting that these drugs may be effective 
in cancer immunotherapy. Our results unveil an unexpected mechanism of tumor evasion 
and introduce new avenues for cancer immunotherapy.
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after the publication date (see http://www.rupress.org/terms). After six months it 
is available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
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is generated by the interplay between the l-arginine metabo-
lizing enzymes arginase (ARG) and nitric oxide synthase 
(NOS) and causes TIL unresponsiveness to stimuli, bypassing 
the TCR (Bronte et al., 2005). We have previously shown 
that drugs affecting ARG and NOS activity reduce intra-
tumoral protein nitration and restore TIL function, suggesting 
efforts, is to modify the lymphocyte TCR via retroviral or 
lentiviral transduction of transgenic receptors, thus enabling 
cells to recognize the tumor-related antigens; alternatively, 
vaccinating the recipient with a tumor-specific antigen can 
enrich for T cells with the desired specificity (Gattinoni et al., 
2006; Morgan et al., 2006; Johnson et al., 2009).
The local immunosuppressive effects of the tumor 
microenvironment are mediated by a variety of mechanisms, 
including expansion of regulatory T cells (T reg cells), 
tumor-associated macrophages, and myeloid-derived sup-
pressor cells (MDSCs), as well as modification of arachidonic 
acid, l-tryptophan, or l-arginine metabolism (Colombo and 
Piconese, 2007; Viola and Bronte, 2007; Grohmann and 
Bronte, 2010). As a result of this suppressive activity, CTLs 
that are fully functional in vitro can be tolerized and thus lose 
their effector function at the tumor site. Nonetheless, com-
bination therapies that link ACT with treatment targeting the 
mechanisms of local immunosuppression, such as lympho-
depletion of the host by either irradiation or chemotherapy 
before cell transfer, promise to overcome this obstacle and are 
being actively pursued (Rosenberg and Dudley, 2009).
The combination of efforts to circumvent the two limiting 
factors described in the previous paragraphs has led to substan-
tial progress, to the point that some of the solutions outlined in 
the previous paragraphs have reached the stage of clinical trials 
(Morgan et al., 2006; June, 2007; Johnson et al., 2009). How-
ever, although there has been progress in ensuring that the 
transferred T cells in ACT are both capable of and undeterred 
from exerting their effector function and clearing the tumor, 
the efficiency of their recruitment to the main tumor and met-
astatic sites has not received as much attention, although any 
clinical therapeutic regimen will be quantitatively dependent 
on the efficiency of such T cell recruitment. Indeed, one of the 
first in vivo studies of T cell trafficking in ACT suggested that, 
even accounting for the effects of immunosuppression, insuffi-
cient T cell recruitment to the tumor site may be a critical fac-
tor in the efficacy of therapy (Breart et al., 2008).
In this context, the first obvious problem is the anarchic 
vasculature of solid tumors, characterized by dilated and 
fragile vessels lacking hierarchical architecture. For example, 
cancer-induced overexpression of Rgs5 and the endothelin 
B receptor in pericytes and endothelial cells, respectively, in-
hibits T cell homing into the tumor parenchyma (Buckanovich 
et al., 2008; Hamzah et al., 2008). However, even when capa-
ble of reaching the tumor, T cells tend to remain at the pe-
riphery, especially in the case of metastasis (Mukai et al., 1999; 
Galon et al., 2006; Boissonnas et al., 2007; Weishaupt et al., 
2007), suggesting that other barriers inhibit the migration of 
CTLs to their cellular targets.
Protein nitration is the consequence of local production 
of reactive nitrogen species (RNS), such as the peroxynitrite 
anion (Szabó et al., 2007; Nathan and Ding, 2010). Several 
human cancers, including prostate, colon, liver (Kasic et al., 
2011), breast, and ovarian (unpublished data) cancers, produce 
RNS, as indicated by their strong expression of nitrated tyro-
sines (nitrotyrosine). In human prostate cancer, peroxynitrite 
Figure 1. Chemical barriers inhibit T cell infiltration within the tumor. 
(A) Two representative serial sections of human colon carcinomas were  
immunostained (brown) for CD3 or nitrotyrosine, as indicated. Bars, 500 µm. 
Noncontiguous regions of interest (ROIs) with dimensions of 157 × 157 pixels 
were selected for either bright nitrotyrosine or CD3 staining and applied to 
serial sections. The percentages of immunoreactive areas for both nitrotyrosine 
and CD3 were obtained for each region of interest. ***, P < 0.001. Data are 
expressed as the means ± SE. (B) Two representative serial sections of human 
undifferentiated nasopharyngeal carcinomas were immunostained (brown) for 
CD3 or nitrotyrosine, as indicated. Bars, 200 µm. (C) CD45.1+ OT-I CTLs were 
adoptively transferred (ACT) to CD45.2+ mice bearing EG7-OVA tumors and,  
4 d later, tumors were removed and stained to visualize nitrotyrosine-positive 
cells (N-Ty) and CTLs (either CD8+ or CD45.1+ cells). The first and second  
columns show the immunohistochemical detection of nitrotyrosine (N-Ty)  
and CD8+ T cells, respectively, whereas the third column shows immuno-
fluorescence staining for CD45.1 (green) and N-Ty (red). Bars, 200 µm.
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We verified that CCL2 was stably modified upon ex-
posure to RNS. In addition, we included CXCL12 in our 
analysis because it belongs to a different chemokine family 
(CXC instead of CC). Chemokines were exposed to RNS 
(peroxynitrite) for 15 min, and the presence of reproduc-
ible modifications (i.e., nitration or nitrosylation) on single 
amino acids was determined by tandem mass spectrometry 
that intratumoral generation of RNS is one of the key mecha-
nisms involved in tumor-induced immune dysfunctions (Bronte 
et al., 2005). Peroxynitrite is also produced by tumor-associ-
ated myeloid cells, including MDSCs (Bronte and Zanovello, 
2005; Gabrilovich and Nagaraj, 2009). Nitration of the TCR 
complex by MDCS-derived RNS impairs tumor-specific 
immunity by reducing T lymphocyte responsiveness to tumor 
antigens (Nagaraj et al., 2007).
In this manuscript, we demonstrate that RNS exert 
additional immunosuppressive activities within the tumor 
microenvironment. Intratumoral RNS production results in 
posttranslational modification of the CCL2 chemokine and 
reduced access of TILs to the inner core of tumor tissues. 
In addition, we provide evidence that targeting RNS produc-
tion in tumors can be exploited as a novel strategy to control 
immune evasion.
RESULTS
RNS can modify chemokines in the tumor microenvironment
Disease-free survival of patients with colorectal cancer strongly 
correlates with an increased ratio of T cells within the tumor 
relative to the tumor margins (Pagès et al., 2005; Galon et al., 
2006). In tissues, protein nitration can be detected using an 
antibody that recognizes nitrotyrosine (Kasic et al., 2011), and 
by using this approach on human colorectal cancer tissue, we 
observed a singular pattern of T lymphocyte distribution that 
was the opposite of nitrotyrosine staining, with TILs concen-
trating at the border of the neoplastic lesions and cancer cells 
staining positive for nitrotyrosine (Fig. 1 A).
Among tumors that we have stained so far, undifferentiated 
nasopharyngeal carcinomas showed wide inter-tumor hetero-
geneity. In fact, in these cancers, we observed samples in which 
T lymphocytes were excluded from areas highly positive for 
nitrotyrosines and other specimens with a very marginal nitro-
tyrosine staining that were broadly infiltrated with T lympho-
cytes (Fig. 1 B). A similar pattern was observed in mice bearing 
an OVA-expressing tumor (EG7) after adoptive transfer of 
OVA-specific OT-I CTLs (Fig. 1 C), indicating that even 
bona fide tumor-specific effector CTLs are unable to reach the 
tumor core and are trapped at the cancer periphery.
Leukocyte migration into inflamed tissues, as in cancer, 
is driven by chemokines, small cytokines with selective che-
moattractant properties (Viola and Luster, 2008). We hypoth-
esized that, in addition to affecting T cell activation (Bronte 
et al., 2005; Nagaraj et al., 2007), RNS restrain TIL access to 
the tumor through posttranslational chemokine modifications.
CCL2 is produced by many cell types, including T cells, 
monocytes, and tumor cells, and it is a chemoattractant for 
myeloid cells, activated CD4+ and CD8+ T cells, and NK cells 
(Allavena et al., 1994; Carr et al., 1994). In addition, it is capa-
ble of triggering granule release from both NK and CD8+  
T cells (Loetscher et al., 1996). Despite being one of the most 
frequently investigated chemokines in tumor immunology, 
the role of CCL2 in tumor immunity remains unclear, and 
several conflicting studies have been published (Rollins and 
Sunday, 1991; Bottazzi et al., 1992; Fridlender et al., 2010).
Figure 2. The RNS-modified CCL2 chemokine can be detected by 
specific antibodies. (A) Macrophages were cultured from the bone mar-
row of either wild-type (wt) or ccl2//ccr2/ (indicated for simplicity as 
ccl2/) mice. After stimulation with IFN- and LPS, macrophages were 
stained for NOS2, CCL2, or N-CCL2 (VHH-12BM). Background fluorescence 
with isotype-matched and secondary antibodies is reported in the graph 
and indicated as bkg. The graphs depict the mean fluorescence (mean ± SE, 
n = 10 ROIs). Statistical analysis was performed by a one-way ANOVA, 
followed by Tukey’s test (***, P < 0.001). Bars, 20 µm. (B) VHH-12BM was 
tested in an ELISA against human CCL-2 and N-CCL2. Unmodified CCL2, 
CXCL12, CCL21, N-CXCL12, and N-CCL21 were used as negative controls. 
Data (A and B) are representative of at least three different experiments 
and are expressed as the means ± SE. ***, P ≤ 0.001. (C) Immunohisto-
chemical staining of serial sections from human prostate (n = 12; top row) 
and colon (n = 12; bottom row) cancers. Cancer cells expressing N-CCL2 
were present within the nitrotyrosine-positive area (bars, 200 µm). The last 
column shows a higher magnification of the same tissues (bars, 20 µm).
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antibody (Fig. 2 A). ELISA results confirmed that 
the new antibody recognized N-CCL2 and not 
nonspecific modifications (nitration/nitrosylation) 
induced by RNS in chemokines (Fig. 2 B).
These results allowed us to evaluate the presence of 
N-CCL2 in human tissues. We obtained positive staining in 
specimens derived from human prostate and colon carcino-
mas (Fig. 2 C), two human cancers known to produce CCL2 
(Hu et al., 2009; Izhak et al., 2010), indicating that N-CCL2 
is expressed in both cancers. Most importantly, these data 
identified a novel posttranslational modification of chemo-
kines that occurs in the human tumor microenvironment.
RNS-modified CCL2 attracts myeloid cells  
but not T lymphocytes
We analyzed the functional properties of N-CCL2. Short-
term exposure of either the human or mouse chemokine 
to RNS had a strong impact on its ability to attract CD8+ T cells. 
Indeed, both human and mouse T cells were unable to mi-
grate toward gradients of N-CCL2 in Transwell assays (Fig. 3 A). 
Similar results were obtained with CXCL12 (Fig. S2), indi-
cating that RNS modification alters the biological properties 
of various chemokines.
In addition to CD8+ T cells, CCL2 attracts monocytes 
and macrophages to sites of inflammation (Serbina et al., 2008) 
and cancer (Sozzani et al., 1995). Moreover, the CCR2–CCL2 
axis is crucial for the recruitment of MDSCs to tumors (Huang 
et al., 2007). Therefore, we analyzed the effects of RNS on 
the chemotactic activity of CCL2 toward myeloid cells. 
(MS-MS) coupled to liquid chromatography (LC-MS/MS). 
Tyrosine-nitrated KEWVQTY*IK and tryptophan-nitrated 
W*VQDSMDHLDK peptides were identified in mouse and 
human CCL2, respectively (where * represents nitration, +45 D; 
Fig. S1, A and B). Tyrosine-nitrated peptides from mouse 
CXCL12 (KPVSLSY*R and WIQEY*LEK; Fig. S1, C and D) 
were also characterized.
To verify the existence of RNS-modified chemokines in 
tumors, we tried to analyze tumor samples by LC-MS/MS, 
but chemokines were expressed in tumors at concentrations too 
low to be detected. Thus, we isolated a single-domain recom-
binant antibody (VHH) from a llama naive library (Monegal 
et al., 2009) that recognized the RNS-modified human and 
mouse CCL2 (N-CCL2). We tested this new reagent on 
bone marrow–derived macrophages that had or had not been 
exposed to a combination of IFN- and LPS to boost NOS2 
expression and, thus, the nitration/nitrosylation of intracellu-
lar proteins (Kurata et al., 1996; Pfeiffer et al., 2001). N-CCL2 
staining was stronger in stimulated macrophages than in rest-
ing ones, whereas CCL2 staining decreased in stimulated cells 
(Fig. 2 A), confirming our initial observations that RNS-
modified CCL2 and CXCL12 are not recognized by com-
mercially available anti-CCL2 or anti-CXCL12 antibodies, 
respectively (not depicted). In these experiments, ccl2//ccr2/ 
macrophages were used to verify the specificity of the N-CCL2 
Figure 3. RNS alter the biological activity of human 
and mouse CCL2. (A and B) Human or mouse CD8+ T lym-
phocytes (A) and human CD14+ or mouse CD11b+ myeloid 
cells (B) were exposed to a gradient of recombinant human 
or mouse CCL2 (100, 10, or 1 ng/ml). Chemokines were either 
untreated (CCL2) or RNS treated (N-CCL2). Transmigrated 
cells were counted, and the results were expressed as fold 
induction over control. Data are representative of three dif-
ferent experiments and are expressed as the means ± SE.  
*, P ≤ 0.05; **, P ≤ 0.01. (C and D) Fluo-4/Fura-Red–loaded 
human T cells (CD14+ or CD8+; A) or CHO cells that were or 
were not expressing human CCR2 (CHO or CHO-CCR2; 
 D) were stimulated with either CCL2 or N-CCL2 and free 
[Ca2+]i was measured by flow cytometry. Ionomycin was 
used as a positive control for the maximal Ca2+ influx. Data 
are representative of one out of three experiments.  
(E) Human CD8+ and CD14+ cells were stained with either 
anti–human CCR2 phycoerythrin-conjugated mAb or with 
its isotypic control. Cell fluorescence was analyzed by flow 
cytometry. The mean fluorescence intensity, normalized to 
isotype control staining, was 13.2 ± 1.7 and 2.3 ± 0.3 for 
hCD14 and hCD8 cells, respectively (P ≤ 0.05). (F) Competi-
tive binding was performed by incubating CD14+ cells or 
CHO-CCR2 cells with 125I-hCCL2 in the presence of various 
concentrations of unlabeled, untreated (), or peroxynitrite-
treated () hCCL2. After incubation, the cell-associated radio-
activity was measured. Data are representative of three 
different experiments and are expressed as the means ± SE.
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and T cells to the nitrated CCL2 were not 
dependent on the expression of different types 
of chemokine receptors. We next considered 
whether these opposite responses could be 
attributed to quantitative rather than qualita-
tive differences. Indeed, we observed that 
CCR2 expression levels were much higher in 
myeloid cells than in CD8+ T cells (Fig. 3 E) 
and that RNS-induced modification resulted 
in an overall decreased affinity of CCL2 for its 
receptor but not in a complete loss of func-
tion (Fig. 3 F). Notably, because of the low 
CCR2 abundance in T cells, we failed to de-
tect measurable binding of either CCL2 or 
N-CCL2 to lymphocytes (unpublished data). 
Altogether, these data suggest that the de-
creased affinity of N-CCL2 for CCR2 is 
functionally irrelevant for myeloid cells ex-
pressing many receptors, but decreased affin-
ity impairs the capacity of T cells to sense the 
modified chemokine.
Our data indicate that RNS can induce 
stable posttranslational modifications in chemo-
kines, which results in alteration of their 
functional properties. The RNS-induced mod-
ifications reduced the binding of CCL2 to 
CCR2 and the chemoattractant effect of 
CCL2 on CD8+ T cells. The fact that monocytes can be at-
tracted by N-CCL2 might explain the selective enrichment 
of myeloid cells, compared with T lymphocytes, in the 
tumor microenvironment.
In vivo modulation of intratumoral RNS production results 
in enhanced TIL infiltration
We speculated that drugs that block intratumoral RNS pro-
duction might interfere with factors that normally inhibit the 
access of T lymphocytes to the tumor mass. There is an ample 
list of compounds with in vitro peroxynitrite-scavenging ac-
tivity but, for many of these molecules, the main activity is 
indirect and dependent on reactions with secondary radicals 
generated by peroxynitrite (Szabó et al., 2007). In any event, 
these compounds mainly act as extracellular traps, and we 
reasoned that molecules that affect RNS production by in-
hibiting the expression of enzymes involved in this process 
The ability of CCL2 to attract either human or mouse my-
eloid cells was affected by RNS in a concentration-dependent 
manner (Fig. 3 B). Indeed, in contrast to what we observed 
with T lymphocytes, myeloid cells migrated efficiently in re-
sponse to a high concentration (100 ng/ml) of RNS-modified 
CCL2, whereas their ability to sense lower concentrations of 
the RNS-modified chemokine (10–1 ng/ml) was reduced. 
In agreement with this result, we found that myeloid cells, but 
not T lymphocytes, responded to 100 ng/ml N-CCL2 with 
a rise in cytosolic calcium similar to that obtained upon stim-
ulation with a control, unmodified chemokine (Fig. 3 C).
We next analyzed calcium responses elicited by either 
CCL2 or N-CCL2 in Chinese hamster ovary (CHO) cells 
that were or were not transfected with human CCR2. Trans-
duction of human CCR2 was sufficient to assure a fully func-
tional binding of both the control and modified chemokines 
(Fig. 3 D), suggesting that the different responses of myeloid 
Figure 4. Improved intratumoral T cell migration 
after in vivo reduction of RNS. (A and B) Immuno-
histochemical staining for nitrotyrosine, NOS2, ARG1, 
or ARG2 (A) or CD3, CCL2, and N-CCL2 (B) in C26GM, 
TRAMP, and EG7 tumor samples obtained from mice 
either treated or not with AT38 for 7 d. The graphs 
represent the quantification of immunoreactive cells or 
areas (Student’s t test, ***, P < 0.001; n = 20). Bars:  
(A) 50 µm; (B, anti-CD3 pictures) 50 µm; (B, anti-CCL2 
and anti-N-CCL2 pictures) 20 µm. Data are representa-
tive of three different experiments and are expressed as 
the means ± SE.
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reduction in nitrotyrosines and N-CCL2, and it enhanced 
the expression of the unmodified chemokine (Fig. 4, A and B). 
The enhanced expression of CCL2 was not a result of in-
creased protein synthesis in the tumor microenvironment 
(Fig. S3), reinforcing the concept that AT38 treatment un-
masked CCL2 that, when otherwise modified by RNS, was 
not recognized by anti-CCL2 antibodies. Thus, we used 
AT38 to prepare the tumor microenvironment for the arrival 
of tumor-specific CTLs.
C57BL/6 (CD45.2) mice were injected s.c. with EG7-
OVA cells and, when the tumor volume was 150 mm3, the 
mice were or were not treated with AT38 for 4 d. This 4-d 
treatment did not modify the tumor volume (307 ± 52 vs. 332 
± 48 mm3 for untreated and AT38-treated mice, respectively). 
OVA257-264-specific CTLs that had been obtained from OT-I 
mouse splenocytes (CD45.1) were then adoptively transferred 
into mice, and AT38 was further administered for an addi-
tional 3 d. AT38 administration allowed tumor invasion by 
antigen-specific CTLs that, as already discussed (Fig. 1 C), 
were otherwise trapped in the surrounding stroma (Fig. 6 A).
Inversion of the intratumoral ratio between CD8+  
T lymphocytes and Foxp3+/CD4+ T reg lymphocytes was 
correlated with the effect of immunotherapy on experimen-
tal melanoma (Quezada et al., 2006), and a high CD8+/T reg 
cell ratio was found to be associated with a favorable progno-
sis in human epithelial ovarian cancer (Sato et al., 2005). We 
thus evaluated the presence of Foxp3+ cells in our experi-
mental system. AT38 treatment did not alter the frequency of 
Foxp3+ cells within the tumor mass but, in contrast to what we 
had observed for antigen-specific CTLs, it caused a significant 
were better candidates for further development. Therefore, 
we designed, produced, and tested several new small mole-
cules to block the in vivo generation of peroxynitrite and, 
among them, AT38 ([3-(aminocarbonyl)furoxan-4-yl]methyl 
salicylate; Suplemental data) possessed the highest activity and 
was thus selected for further in vivo studies.
We exploited three different tumor models to analyze 
the role of RNS in tumor immunity: a colon carcinoma 
(C26GM), a mouse thymoma engineered to express OVA as 
a tumor antigen (EG7-OVA), and a prostate cancer sponta-
neously arising in transgenic adenocarcinoma of the mouse 
prostate (TRAMP) mouse, which is considered a suitable 
model for evaluating results transferable to the clinical setting 
(Kaplan-Lefko et al., 2003). Mice injected s.c. with either 
C26GM or EG7-OVA cells and TRAMP mice (24 wk of 
age) were treated with AT38 for 7 d before tumor tissue col-
lection. The intratumoral expression of nitrotyrosines and 
the enzymes NOS2 and ARG1, for C26GM and EG7-OVA 
tumors (De Santo et al., 2005), or NOS2 and ARG2, for 
TRAMP tissues (Bronte et al., 2005), decreased after in vivo 
administration of AT38 (Fig. 4 A).
Based on our hypothesis that RNS modification of 
chemokines might be responsible for the inability of T cells 
to reach the tumor core, we compared the T cell contents of 
tumors from mice that were or were not treated with AT38 
and found that treatment had indeed significantly increased 
the number of T cells inside the tumors (Fig. 4 B). Notably, 
treating mice with AT38 induced a strong reduction in intra-
tumoral N-CCL2 expression, which was paralleled by in-
creased immunoreactivity for CCL2 (Fig. 4 B).
To prove that CCL2 nitration/nitrosylation was indeed 
responsible for defective TIL infiltration, we used two differ-
ent experimental approaches. On the one hand, we performed 
the experiment shown in Fig. 4 in ccr2/ mice and found 
that AT38 did not improve infiltration of ccr2/ TILs in 
EG7-OVA tumors (Fig. 5 A). On the other hand, we injected 
unmodified CCL2 within the mass of untreated MCA-203 
tumors and observed TIL recruitment into the tumor mass 
(Fig. 5 B). These data indicate that the mechanism by which 
AT38 improves TIL infiltration is based on unmodified chemo-
kine (CCL2) bioavailability.
In vivo modulation of intratumoral RNS enhances tumor 
eradication by ACT
Altogether, the data described in the previous section suggest 
that AT38 administration in tumor-bearing mice could pre-
condition the tumor microenvironment and thus support 
cancer elimination by adoptively transferred, tumor-specific 
CTLs. To verify this hypothesis, we initially used EG7-OVA 
tumor cells because specific antitumor CTLs can be obtained 
from OT-I transgenic mice; the CD8+ T cells isolated from 
these mice express a clonal TCR specific for the SIINFEKL 
peptide of OVA. Moreover, this tumor had been already used 
in previous lymphocyte trafficking studies (Boissonnas et al., 
2007; Breart et al., 2008). As already described, treating mice 
bearing EG7-OVA tumors with AT38 caused an intratumoral 
Figure 5. CCL2 nitration/nitrosylation prevents intratumoral T cell 
infiltration. EG7 tumor samples obtained from either wt or ccr2/ mice, 
treated or not with AT38 for 7 d (A) or MCA-203 tumor samples obtained 
from wt mice that had received intratumoral injections of CCL2 (0.5 µg in 
hydrogel; B) were stained for CD3 by immunohistochemistry. The graphs 
represent the quantification of immunoreactive cells (Student’s t test; ***,  
P < 0.001; n = 20). Bars, 50 µm. Data are representative of three different 
experiments and are expressed as the means ± SE.
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endogenous antitumor response in immunocompetent mice, 
independent of ACT (Fig. 6 C and Fig. S4 B).
A major goal of all immunotherapeutic approaches is the 
establishment of long-term protection that will not only 
reduce the tumor burden but also eliminate all cancer cells. 
We therefore analyzed the establishment of antitumor mem-
ory responses in mice that had rejected the first tumor chal-
lenge. Mice that were cured by administration of AT38 or 
the combined immunotherapeutic protocols (AT38 plus 
ACT) were challenged subcutaneously after 100 d with the 
same EG7-OVA cells in one flank and an antigenically unre-
lated sarcoma (MCA-203) lacking OVA expression in the 
contralateral flank. Long-term survivors that had received 
AT38 plus ACT completely rejected the EG7-OVA but not 
the MCA-203 tumors, whereas mice surviving after adminis-
tration of only AT38 did not reject any of the tumors, a clear in-
dication that, although AT38 allowed an immune-mediated 
rejection of the first tumor, a memory response was generated 
only in mice that received ACT (Fig. 6 D). These results, 
T reg cell accumulation at the boundary of the neoplastic 
lesion (Fig. 6 A). The CD8+/T reg cell ratio was thus in-
creased at the tumor core but decreased at the periphery.
We next asked whether the combination of AT38 and 
ACT might enhance the therapeutic effect. ACT alone in 
mice bearing 10-d-old (300 mm3) EG7-OVA tumors had no 
significant impact on tumor growth or mouse survival (Fig. 6 B 
and Fig. S4 A). Mice treated with AT38 alone had a modest 
but significant increase in survival, resulting in a cure rate of 
20%. However, ACT preconditioned with AT38 produced 
a significant overall prolongation of survival and a cure rate of 
60% of the tumor-bearing mice (Fig. 6 B and Fig. S4 A).
To understand whether the increased survival rate ob-
served in the mice treated with AT38 only was the result of 
either a direct antitumor effect or the activation of endoge-
nous immune responses, EG7-OVA cells were inoculated 
into either control or immunodeficient Rag2/c/ mice 
that had been treated with AT38 according to the previous 
protocol. The results clearly showed that AT38 stimulates an 
Figure 6. Inhibition of RNS production promotes 
tumor infiltration and therapeutic effectiveness of 
adoptively transferred, tumor-specific CTLs. EG7-
OVA tumor-bearing mice (n = 18) were either un-
treated or treated with AT38 for 7 d (30 mg/kg/d; AT38 
only) with adoptive transfer of 2 × 106 CTLs (when the 
tumor volume was 300 mm3; CTLs only) or with a 
combination of CTLs and AT38 (4 d before and 3 d 
after ACT; CTLs+AT38). (A) Mice were euthanized and 
tumors removed to analyze the frequency and local-
ization of CD3+, CD8+, CD45.1+, or Foxp3+ T cells within 
the tumors. Immunohistochemical images are shown 
for CD3+ T cells only, whereas the graphs represent the 
quantification of immunoreactive CD3+, CD8+, 
CD45.1+, or Foxp3+ T cells within the tumor and in the 
tumor-surrounding stroma. Data are expressed as the 
means ± SE. (Student’s t test, *, P ≤ 0.05; **, P ≤ 0.01.***, 
P < 0.001; n = 20). Bars, 50 µm. (B) Tumors were mea-
sured blindly using digital calipers. Mice were eutha-
nized when the tumor area reached 1,000 mm3. 
Mantel-Haenszel statistics: CTLs versus AT38, P = 
0.004; CTLs versus AT38+CTLs, P = 0.00003; AT38 ver-
sus AT38+CTLs, P = 0.029. (C) C57BL/6 (n = 10) and 
Rag2/c/ (n = 10) mice were injected with 0.5 × 
106 EG7-OVA cells. When the tumor volume reached 
300 mm3, the mice were treated or not with AT38 
(30 mg/kg/d) for 7 d. Mantel-Haenszel statistics: 
C57BL/6J AT38-treated versus C57BL/6J, untreated,  
P = 0.0003; Rag2/c/, AT38-treated versus 
Rag2/c/, untreated, P = 0.352. (D) Mice that had 
been cured by either AT38 treatment (n = 4) or by the 
combined immunotherapeutic protocols (AT38 plus 
ACT, n = 6) were subcutaneously challenged after 100 d 
with the same EG7-OVA cells (0.5 × 106 cells/mouse), 
in one flank and an antigenically unrelated sarcoma 
(MCA-203, 106 cells/mice) that lacks OVA expression in 
the contralateral flank. The growth curve of the tumors 
is shown as an increase in the tumor volume over time from the day of the second tumor challenge. Data (A–D) are from two independent, cumulated experi-
ments. In D, mean tumor volumes and S.E. are reported.
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T cells do not freely travel within a tumor; instead, they 
remain trapped in the stroma surrounding the cancer cells 
(Mukai et al., 1999; Galon et al., 2006; Boissonnas et al., 2007; 
Weishaupt et al., 2007). There are alterations in the endothe-
lium of the tumor microvasculature (Weishaupt et al., 2007; 
Buckanovich et al., 2008; Hamzah et al., 2008) that are re-
sponsible for the reduced T cell extravasation and homing in 
the neoplastic lesion. Additionally, when the micropattern of 
T cell infiltration within the tumor is analyzed, other factors 
seem to be involved in the selective lack of direct contact 
between CTLs and tumor cells.
The homing of effector T cells to inflamed tissues and 
tumors depends on the concerted action of adhesion molecules, 
such as LFA-1 and VLA-4, and specific chemokines that regu-
late both leukocyte extravasation and migration toward 
specific areas (Springer, 1994; Butcher and Picker, 1996; 
Frederick and Clayman, 2001; Homey et al., 2002). Interest-
ingly, in addition to inflammatory and endothelial cells, tumor 
cells themselves are capable of producing CTL-attracting 
chemokines (Murphy, 2001; Harlin et al., 2009). The role 
of chemokines in the tumor microenvironment is multi-
faceted in that chemokines can attract dendritic cells and lym-
phocytes, which may promote antitumor immunity and thus 
inhibit tumor growth; however, chemokines can also pro-
mote tumor growth and progression, angiogenesis, and 
metastasis (Balkwill and Mantovani, 2001). Thus, alterations 
in the expression or function of chemokines may have a tre-
mendous impact on tumor development. Oncogenes might 
directly control the expression of chemokines that are crucial 
for T cell recruitment. For example, abnormalities in the 
EGFR–Ras signaling pathway in keratinocytes suppress 
the production of CCL27, and the consequent reduction in 
leukocyte recruitment could be partly responsible for tumor 
escape from the immune system (Pivarcsi et al., 2007).
However, the activity of chemokines is controlled not 
only through the regulation of their expression but also 
through silent decoy receptors and by posttranslational modi-
fications, including proteolytic processing, glycosylation, de-
amination, or citrullination of the chemokines themselves (Loos 
et al., 2009). In this manuscript, we describe a novel mechanism 
of tumor escape based on the posttranslational modification of 
intratumoral chemokines, which can be pharmacologically tar-
geted to improve the efficacy of immunotherapy. Our data 
indicate that CCL2, an inflammatory chemokine involved in 
the recruitment of CTLs and myeloid cells to tumors (Sozzani 
et al., 1995; Brown et al., 2007; Huang et al., 2007; Harlin 
et al., 2009), is nitrated/nitrosylated in human and mouse 
cancers. Interestingly, RNS-induced modifications change 
the functional properties of the chemokine so that it can no 
longer attract tumor-specific CTLs but can still recruit my-
eloid cells to the tumor. Although, for technical reasons, we 
could not overexpress CCR2 in CD8+ T cells or reduce its 
expression in monocytes (electroporation dramatically down-
modulates CCR2 expression), the reduction in CCL2 affinity 
for its receptor by nitration suggests that the differential re-
sponses of lymphocytes and monocytes to N-CCL2 may be 
together with those from the experiments in immuno-
deficient mice, suggest that NK cells, a short-memory adaptive 
immune response, or a combination of both are responsible 
for the effects of AT38 on tumor growth when adminis-
tered alone in tumor-bearing mice.
To further corroborate the activity of AT38, we repeated 
the ACT experiments using CTLs that recognize the tumor 
antigen mouse telomerase (mTERT). Adoptive transfer of 
mTERT-specific CTLs in wild-type mice bearing 200-mm3 
subcutaneous nodules of MCA-203 fibrosarcoma had no 
effect on tumor regression, unless preceded by myeloid and 
lymphoid ablation (Marigo et al., 2010; Ugel et al., 2010). 
However, AT38 allowed mTERT-specific CTLs to reject the 
tumor even in the absence of lympho-myeloablation (Fig. 7 A). 
The surviving mice were challenged on day 60 with the same 
fibrosarcoma, which was promptly rejected (Fig. 7 B), indi-
cating the presence of a persistent antitumor immunity.
DISCUSSION
Of the rate-limiting steps in effective active immunotherapy, 
recruitment and activation within the tumor milieu are now 
viewed as the most relevant. Several studies have shown that 
Figure 7. Inhibition of RNS production boosts ACT with mTERT-
specific CTLs. (A) MCA-203 fibrosarcoma-bearing mice (n = 8) were  
either untreated or treated with AT38 for 7 d (AT38) with adoptive trans-
fer of 2 × 106 CTLs specific for the mTERT antigen (when the tumor vol-
ume reached 300 mm3; CTLs) or with a combination of CTLs and AT38 
(4 d before and 3 d after ACT; CTLs+AT38). Mantel-Haenszel statistics: 
CTLs versus AT38, P = 0.18; CTLs versus AT38+CTLs, P = 0.00009; AT38 
versus AT38+CTLs, P = 0.018. (B) Mice that had been cured by the com-
bined immunotherapeutic protocols (AT38 plus ACT, n = 6) were subcutane-
ously challenged after 60 d with the same MCA-203 cells (106 cells/mice) 
in one flank and an antigenically unrelated EG7-OVA (0.5 × 106 cells/mice) 
in the contralateral flank. The tumor growth curve is shown as an increase 
in the tumor volume over time from the day of the second tumor chal-
lenge. Data are from two independent, cumulated experiments. In B, 
mean tumor volumes and S.E. are reported.
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could dramatically improve the efficacy of ACT protocols. 
Indeed, we found that AT38 enabled ACT to reject solid 
tumors, even at low T cell transfer doses, which are nor-
mally ineffective. Thus, RNS-inhibiting molecules represent 
a bona fide new class of adjuvants specific for the immuno-
therapy of cancer.
In a recent survey of intratumoral CTL trafficking by two-
photon imaging, limited numbers of antigen-activated OT-I 
CD8+ T lymphocytes caused regression of OVA-expressing 
tumors by engaging in multiple, long-lasting interactions with 
tumor cells (Breart et al., 2008). We did not observe direct 
antitumor activity in our transferred antigen-activated OT-I 
CTLs, but the stages during which the tumors were treated 
were rather different in the two studies (the tumors were 10 d 
old and 300 mm3 in our study compared with 5 d old and 
20 mm3 in the previous one). The results of the two studies 
might suggest that the ability to migrate within tumor tissues 
is progressively impaired with tumor growth, likely because of 
progressive accumulation of RNS-mediated modifications of 
target chemokines. The hypoxic microenvironment gener-
ated with tumor growth could play a key role in this process. 
Hypoxia is known to induce NOS2 up-regulation and per-
oxynitrite production under ischemic conditions, either with 
or without malignant transformation (Melillo et al., 1995; 
Suzuki et al., 2002). Recently, hypoxia-inducible factor 1 
was shown to drive the program leading to ARG1 and NOS2 
up-regulation in mouse tumor-associated macrophages (Corzo 
et al., 2010; Doedens et al., 2010). It is therefore possible that 
T cell motility is preserved at the margins of a small tumor, 
thus explaining the data obtained using intravital microscopy 
(Breart et al., 2008), but is severely impaired within an estab-
lished, hypoxic cancer.
In similar work analyzing the infiltration of OVA-specific 
CTLs by in vivo imaging, it was noted that 10-d-old tumors 
could be cured with a large dose (107) of purified naive 
OT-I-GFP cells (Boissonnas et al., 2007). At an early phase 
after ACT (3–4 d), OT-I CTLs remained at the periphery 
of the tumor, whereas at a later phase (5–6 d), OT-I CTLs 
began to infiltrate within the tumor, provided that neoplastic 
cells expressed the OVA tumor antigen (Boissonnas et al., 
2007). Interestingly, OT-I-naive CD8+ T cells favored the 
infiltration by polyclonal CTLs activated with OVA antigen 
in vitro before co-transfer, suggesting that OT-I cells could 
induce a change in the tumor microenvironment and make it 
permissive for infiltration by other activated T cells. ACT 
with high numbers of CTLs possessing a high-avidity TCR 
for a tumor antigen is known to result in the eradication of 
large, established tumors through a mechanism that involves 
killing the stromal cells that cross-present the same tumor 
antigen (Zhang et al., 2008). In accordance, by titrating the 
number of OT-I CTLs, we established that a threefold in-
crease in the number of cells inoculated into tumor-bearing 
mice, from 2 × 106 to 6 × 106, was sufficient to unveil an initial 
but significant effect of ACT on tumor progression (unpub-
lished data). This therapeutic activity correlated with an increase 
in the number of cells producing CCL2 (unpublished data), 
explained by the different CCR2 expression levels in the two 
cell populations.
Peroxynitrite reacts with several amino acids and directly 
modifies cysteine, methionine, and tryptophan, whereas tyro-
sine, phenylalanine, and histidine are modified through inter-
mediary secondary species (Abello et al., 2009). Our in vitro 
experiments identified reproducible modifications on tyrosine 
and confirmed that nitration of tryptophan occurs. These 
findings support MS-MS as the gold standard for localizing 
nitrated amino acids. However, even if sensitivity of the MS 
instrumentation has increased (LOD < fmol level), it is not yet 
sufficient for detecting nitration in vivo (Abello et al., 2009).
ARG and NOS co-activation within the same environ-
ment can lead to production of several ROS and RNS. For 
example, superoxide (O2) might be alternatively released 
from the NOS2 reductase domain at a low l-arginine envi-
ronmental concentration as a result of enhanced ARG1 activity 
(Xia and Zweier, 1997; Xia et al., 1998; Bronte et al., 2003; 
Bronte and Zanovello, 2005), such as in the tumor micro-
environment (Grohmann and Bronte, 2010). This phenom-
enon is known as the uncoupled reaction and, in addition to 
NOS2, NOS1 and NOS3 produce O2 in the presence of a 
low availability of l-arginine (Andrew and Mayer, 1999). 
Once generated, O2 reacts immediately with residual NO, 
leading to the formation of peroxynitrite (Nathan and Ding, 
2010). Release of peroxynitrite from myeloid cells, activated 
by tumors and migrated to draining lymph nodes, might 
nitrate tyrosine residues in the TCR and CD8 receptors, result-
ing in decreased recognition of peptide–MHC complexes by 
the TCR (Nagaraj et al., 2007). It has been suggested that, in 
this context, peroxynitrite is generated in tumor-conditioned 
MDSCs by the combined activity of an NADPH oxidase 
(likely the Nox2 member of this family of oxidases) and an 
NOS isoform different from NOS2 (Nagaraj et al., 2007).
Nitroaspirin effect has been associated with a profound 
inhibition of both ARG1 and NOS2 activity in spleen and 
tumor-associated myeloid cells; although NO released by 
nitroaspirin was essential for NOS inhibition, as previously 
demonstrated (Griscavage et al., 1995; Mariotto et al., 1995), 
the aspirin-spacer portion was responsible for the ARG inhi-
bition (De Santo et al., 2005). Moreover, nitroaspirin (but 
not aspirin) inhibits the catalytic subunit of NADPH oxidase 
and superoxide production induced by LPS, TNF, and IL-1 
in pulmonary artery vascular smooth muscle and endothelial 
cells (Muzaffar et al., 2004). However, despite all of these 
positive activities, nitroaspirin was poorly effective as an ad-
juvant for ACT in the present work (unpublished data). For 
this reason, we designed novel drugs with different structural 
changes and alternative NO-donating groups. This process of 
screening culminated in the identification of AT38 as the 
lead compound (Supplemental data).
Our results indicate that in vivo administration of AT38 
to tumor-bearing mice controls RNS generation and induces 
a massive T cell infiltration within the tumor microenviron-
ment. On the basis of these data, we reasoned that AT38, 
by removing the chemical barriers raised by cancer growth, 
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with 10% FCS, 1% penicillin, and 1% l-glutamine and cultured in the pres-
ence of 0.5 mg/ml G418.
Mouse OVA257-264 CTLs derived from OT-I splenocytes were stimu-
lated once with 1 µM specific OVA257-264 (SIINFEKL) Kb-restricted peptide. 
Cultures were grown for 7 d in DME–10% fetal bovine serum contain-
ing 20 IU/ml of recombinant human IL-2 (Novartis) at 37°C in 5% CO2. 
Mouse TERT198-205 CTLs were obtained from a mixed leukocyte peptide 
culture set up with vaccinated TRAMP splenocytes in the presence of 0.1 µM 
mTERT198-205 peptide (VGRNFTNL). Peptides were purchased from JPT 
Peptide Technologies. Protocols allowing the animal experiments have 
been approved by the local ethical committee and communicated to the 
relevant Italian authority (Ministero della Salute, Ufficio VI), in compliance 
of Italian Animal Welfare Law (Law n 116/1992; http://www.unipd 
.it/unipdWAR/page/unipd/organizzazione1/it_Book75_Page3).
Bone marrow–derived macrophages. Tibias and femurs from either 
BALB/c or CCL2/CCR2/ mice were removed using sterile technique, 
and the bone marrow was flushed. The red blood cells were lysed with ammo-
nium chloride. To obtain macrophages, 106 cells were plated on glass coverslips 
into 6-well plates in medium supplemented with 40 ng/ml M-CSF and main-
tained at 37°C in a 5% CO2-humidified atmosphere for 4 d. Macrophages were 
then cultured for an additional 6 h in the presence of 25 ng/ml IFN- (Pepro-
Tech) followed by a 48-h incubation with 1 µg/ml LPS (Sigma Aldrich).
Tumor challenge. BALB/c mice were inoculated s.c. on the right flank 
with 0.5 × 106 C26GM cells. C57BL/6 and Rag2/c/ mice were inoc-
ulated s.c with 0.5 × 106 EG7-OVA cells. C57BL/6 mice were inoculated 
s.c with 106 MCA-203 cells.
CTL assay. To generate in vitro CTLs, 6 × 105 splenocytes from BALB/c 
mice were incubated with 6 × 105 -irradiated C57BL/6 splenocytes. After 
5 d, the cultures were tested for their ability to lyse an allogeneic target in a 
5-h 51Cr-release assay. The percentage of specific lysis was calculated from 
the triplicate sample as follows: (experimental cpm  spontaneous cpm)/
(maximal cpm  spontaneous cpm) × 100. Lytic units (LU) were calculated 
as the number of cells producing 30% specific lysis of 2,000 target cells/106 
effector cells (L.U.30/106 cells). When present, the nonspecific lysis of con-
trol targets was subtracted.
Proliferation assay. BALB/c splenocytes (7.5 × 105 cells/well) were cul-
tured in 96-well flat-bottom plates (Falcon; BD) and stimulated with 1 µg/ml 
of plate-coated anti-CD3 and 5 µg/ml soluble anti-CD28 mAbs. The drugs 
were used at concentrations that lacked toxicity in a control culture (the 
concentration range was 3–200 µM). After 3 d of incubation, the cultures 
were pulsed with 1 µCi/well 3HTdR (PerkinElmer) for 18 h, and 3HTdR 
incorporation was measured by scintillation counting. Data are expressed as 
cpm (means ± SD) of triplicate cultures.
Adoptive cell transfer (ACT). The effects of ACT in mouse transplantable 
tumor models were investigated in C57BL/6 and Rag2/c/ mice after an 
s.c. challenge with 5 × 105 EG7-OVA cells. When the tumor area reached 
300 mm3, the mice were treated with either 30 mg/kg/d of AT38 in 1% 
carboxymethyl cellulose/ethanol (vehicle) or vehicle alone through a double 
i.p. injection. This treatment was repeated every day for 4 d. After that, the 
mice were treated with 2 × 106 of antigen-activated OVA257-264 CTLs 
through i.v. injection. At the time of the CTL transfer, the mice were in-
jected with 30,000 IU of recombinant human IL-2, administered twice a day 
i.p for 3 consecutive days. A group of mice was also treated with AT38 for 
3 d after ATC. The tumors were measured on blind using digital calipers. The 
mice were euthanized when tumor area reached 1,000 mm3.
Hydrogel preparation and injection. Biodegradable, injectable, and 
photo-cross-linkable hydrogel was prepared as previously described (Rossi 
et al., 2011). C57BL/6 mice were inoculated s.c with 106 MCA-203 cells. 
40 mg/liter of the polymeric hydrogel solution was photoactivated using a 
suggesting that the massive inflammation and chemokine 
production obtained through the transfer of a large number 
of CTLs can shift the balance of the tumor microenviron-
ment from inhibition to activation of antitumor immune re-
sponses. However, it must be pointed out that, in a true clinical 
setting, many tumor antigens are self-antigens, and the T cell 
immune responses raised against these antigens are often of 
low affinity. These low-affinity CTLs can recognize peptide-
pulsed target cells but often fail to recognize endogenous an-
tigens on tumor cells, which are usually presented at much 
lower concentrations, as we recently showed for the mela-
noma antigen TRP-2 and the ubiquitous tumor antigen 
TERT (De Palma et al., 2004; Mennuni et al., 2008; Ugel 
et al., 2010). It is thus highly unlikely that tumor antigen–
specific, low-avidity CTLs trigger the event leading to com-
plete regression of the tumor (Mennuni et al., 2008; Ugel 
et al., 2010), unless a high number of CTLs are administered, 
as required by many clinical ACT protocols (Rosenberg 
et al., 2008). The data shown in this paper on the combina-
tion of AT38 and ACT with mTERT-specific CTLs (Fig. 7 A) 
suggest that the use of molecules that destroy the chemical 
barriers raised by the tumor and facilitate CTL infiltration 
may constitute a feasible strategy for improving the efficacy 
of cancer immunotherapy.
MATERIALS AND METHODS
Mice, cell isolation, and cell lines. C57BL/6 (H-2b) and BALB/c (H-2d) 
mice were purchased from Charles River. Rag2/c/ mice (H-2b) were 
purchased form Taconic. TRAMP mice (H-2b) were a gift from N.M. 
Greenberg (Fred Hutchinson Cancer Research Center, Seattle, WA). OT-1-
CD45.1 (H-2b) mice were obtained by crossbreeding C57BL/6-Tg(TcraTcrb) 
1100Mjb/J mice (The Jackson Laboratory) and C57BL/6-CD45.1 mice, a 
gift from M.C. Colombo (Istituto Tumori, Milan, Italy). The ccl2/ccr2/ 
mice (Noda et al., 2006) were a gift from E.S. Mocarski (Emory Vaccine 
Center, Atlanta, GA). The ccr2/ mice were a gift from M. Locati (Humanitas 
Research Institute, Milan, Italy).
The C26GM cell line was derived from the C26 colon carcinoma (H-2d) 
line genetically modified to release GM-CSF (Bronte et al., 2003). The 
C26-GM cells used in this study produced GM-CSF at levels of 10–15 ng/ml 
from 106 cells in 48 h. The EG-7-OVA (H-2b) and MCA-203 fibrosarcoma 
(H-2b) cell lines were obtained from the American Type Culture Collection. 
These cell lines were grown in DME (Invitrogen) supplemented with 2 mM 
l-glutamine, 10 mM HEPES, 20 µM 2-mercaptoethanol, 150 U/ml strep-
tomycin, 200 U/ml penicillin, and 10% heat-inactivated FBS (Invitrogen). 
MSC-2 cells were generated as previously described (Apolloni et al., 2000) 
and cultured in RPMI medium supplemented with 2 mM l-glutamine, 
1 mM sodium pyruvate, 150 U/ml streptomycin, 200 U/ml penicillin, and 
10% heat-inactivated FBS (Bichrom).
Human PB CD8+ T cells and CD14+ monocytes were sorted by nega-
tive selection using the RosetteSep kit (STEMCELL Technologies) and the 
Monocyte Isolation kit II (Miltenyi Biotec), respectively, on different 
healthy donors. Cells were cultured in RPMI 1640 medium (Invitrogen) 
supplemented with 10% FCS, 2 mM l-glutamine, 100 U/ml penicillin, 
and 100 mg/ml streptomycin.
Mouse CD11b+ cells were sorted from healthy mice by positive selec-
tion using CD11b+ microbeads (Miltenyi Biotec). CTLs recognizing -gal 
obtained from a C57BL/6 mouse immunized with pcmv--gal by in vitro 
stimulation with the -gal DAPIYTNV peptide and limiting dilution clon-
ing were cultured in complete DME supplemented with 10% FBS and 
20 U/ml human recombinant IL-2 (rh-IL-2; Chiron Corporation). CHO-
CCR2 cells were cultured in DME-F12 medium (Invitrogen) supplemented 
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according to the manufacturer’s instructions. A 10-µl aliquot of the peptide 
mixture was applied to LC-MS/MS.
MS analysis. One-dimensional LC-MS analyses of the tryptic digest were 
performed with a modified configuration of the ProteomeX 2D LC-MS 
workstation (Thermo Fisher Scientific). A 10-µl aliquot was directly loaded on 
a reversed-phase column (Biobasic-18, 0.180 i.d. × 100 mm, 5 µm, 300 Å; 
Thermo Fisher Scientific) and separated with an acetonitrile gradient (eluent A, 
0.1% formic acid in water; eluent B, 0.1% formic acid in acetonitrile); the 
gradient profile was 5% eluent B for 1 min followed by 5–65% eluent B gradi-
ent within 30 min. The peptides eluted from the C18 column were directly 
analyzed with a linear ion trap LTQ mass spectrometer equipped with nano-
spray (Thermo Fisher Scientific). The main MS conditions were the following: 
heated capillary at 185°C, ion spray at 3.0 kV, and capillary voltage at 38 V. 
Spectra were acquired in the positive mode (in the range of 400–2,000 m/z) 
using data-dependent scan and dynamic exclusion modes for MS/MS analysis 
(collision energy 35%, three most abundant ions, minimum count 3).
Isolation of VHHs against N-CCL2. Recombinant VHHs against RNS-
modified CCL2 were isolated from a llama single-domain naive library 
(Monegal et al., 2009) after three rounds of panning. In all three rounds, 
phages were predepleted against nonmodified CCL2 and the peroxynitrite 
reaction crude before exposing them to N-CCL2.
The following were coated on a MaxiSorp 96-well plate: 1 µg of non-
modified CCL2 and 1 mM peroxynitrite reaction crude (for depletion) or 1 µg 
human N-CCL2. The wells were blocked with 3% BSA in PBS 0.1% Tween 
at room temperature for 2 h and washed three times with PBS before the 
addition of naive library phages. In the first round, 3 × 1015 phages were depleted 
against CCL2 and the peroxynitrite crude before using them for panning against 
the RNS-modified CCL2. After a 2-h incubation at room temperature, the 
wells were washed 10× with PBS 0.1% Tween and 10× with PBS, and bound 
phages were eluted with 0.1 M triethylamine, pH 11.0. The eluted phages 
were titrated, used to infect TG1 cells, and plated on 2xTY ampicillin, glucose 
large square plates. Colonies were scraped, infected with 1010 KM13 helper 
phage, and grown overnight, and phage particles were precipitated from the 
culture supernatant with 4% PEG 6000 and 0.5 M NaCl. The new sublibrary 
of phages was resuspended in sterile PBS, titrated, depleted against CCL2 and 
peroxinytrite, and used in the second round of panning. The same complete 
procedure was repeated for the third round, with the following modifications: 
panning alternating 3% BSA in PBST and 2% skim milk in PBS were alter-
nated as blocking agents, and 0.5 µg of RNS-modified CCL2 was used instead 
of 1 µg. In each round of panning, the enrichment of the phage sublibrary ob-
tained was calculated as the ratio of output/input phage. A total of 96 single 
clones were analyzed by ELISA after the third round of panning. Colonies 
were grown at 37°C in 2xTY supplemented with 0.1 mg/ml ampicillin and 
0.1% glucose for 3–4 h, induced with 1 mM IPTG and incubated overnight at 
30°C. Cultures were harvested and periplasmic lysates containing soluble HA-
tagged VHHs were diluted 1:3 and incubated with 10 µg/ml mouse superna-
tant anti-HA 12CA5 for use in ELISA. MaxiSorp 96-well plates (Nunc) were 
coated with either N-CCL2 or CCL2 or with crude reaction (peroxynitrite) 
in 50 mM sodium carbonate buffer as a negative control (4°C). Antigens were 
used at the same concentrations as for panning. The plates were blocked with 
2% BSA for 2 h, washed three times with PBS, and incubated 
1 h with periplasmic lysates. The plates were then washed three times with 
PBS-0.1% Tween and treated with anti–mouse HRP conjugate (Bio-Rad 
Laboratories) for 1 h at room temperature. After washing three times with 
PBST, the reaction was developed by adding TMB (Thermo Fisher Scien-
tific), and the absorbance at 450 nm was measured after a 20-min incubation. 
Clones that had an absorbance value in the N-CCL2 coated plate that was sig-
nificantly different from the value of both CCL2 or the crude reaction-coated 
plate were used for immunohistochemical analysis.
Quantitative (q) RT-PCR. Total RNA was isolated from the tumor 
tissue of EG7-OVA tumor-bearing mice that were or were not treated 
with 30 mg/kg/d of AT38 using the RNAspin Mini RNA Isolation kit 
366-nm light source for 30 s (BlueWave 50 lamp; Dymax). Preactivated 
polymeric solution was injected through a Hamilton syringe (GA 22s/ 
51 mm/PST2) for in situ cross-linking and hydrogel formation. Hydrogel 
containing 0.5 µg mCCL2 (R&D Systems) or not was inoculated within the 
tumor. The day after the inoculation, the tumors were explanted, fixed in 
PLP fixative (paraformaldehyde/lysine/periodate), cryoprotected in 30% 
sucrose, and frozen in OCT. Tumor samples were cut with a cryostat (6 µm), 
fixed with acetone for 3 min, and stained with an anti-CD3 polyclonal anti-
body (1:50; Dako). The appropriate secondary antibody was used.
Chemokine nitration/nitrosylation. Recombinant human and mouse 
CXCL12 and CCL2 were purchased from R&D Systems. Chemokine nitra-
tion/nitrosylation was performed by mixing the recombinant protein 
(CXCL12 or CCL2) with 1 mM peroxynitrite (Millipore) at 37°C for 15 min 
in a final volume of 100 µl PBS containing 0.1% BSA (Sigma-Aldrich). After 
incubation, the samples were dialyzed overnight using the Slide-A-Lyzer 
Dialysis cassette kit, 3,500 MWCO (Thermo Fisher Scientific), preparing 
2 liter PBS containing 0.1% BSA according to the kit’s instructions. The next 
day, chemokines were collected from the dialysis cassettes and used for assays.
Chemotaxis assay. Human T cells (CD3+ and CD8+), human CD14+ 
cells, mouse CD11b+ cells, or mouse CD8+ T cells were collected and 
washed three times in basal medium (serum-free medium containing 0.1% 
BSA). The cells were seeded in the upper chamber of a 3-µm pore size 
Transwell plate (Corning) in basal medium. The lower chambers were filled 
with basal medium alone or basal medium containing untreated or RNS-
modified dialyzed chemokine (CXCL12, 50 ng/ml; CCL2, 20 or 100 ng/ml). 
After 3 h at 37°C, the number of cells that had migrated into the lower 
chamber was estimated by flow cytometry on a FACSCalibur system (BD).
Binding assays. CCL2 competitive binding was performed by incubating 
3 × 105 CHO-K1 cells stably transfected with human CCR2 or 2.5 × 105 
human monocytes with 100 pM 125I-CCL2 in the presence of different con-
centrations of unlabeled CCL2, N-CCL2, or CXCL8 in binding buffer 
(DME-F12, 4 mM Hepes, pH 7.4, and 1% BSA) at 4°C for 2 h. After incu-
bation, the cell-associated radioactivity was measured. To estimate the Kd 
(equilibrium dissociation constant) of CCL2, the homologous competitive 
binding and N-CCL2 inhibition curves were determined by nonlinear re-
gression using a one-site competitive binding equation in Prism software 
(3.0a; GraphPad Software).
Calcium measurements. Human CD8+ or CD14+ cells or CHO-K1/
CCR2 cells were loaded with 4 µg/ml Fluo-4 AM and 10 µg/ml Fura Red 
AM for 30 min at 37°C in 1% FCS-RPMI 1640 medium. Cells were washed 
once and resuspended in 1% FCS HBSS medium. After washing, the cells were 
kept at room temperature (25°C) in the dark. A 500-ml aliquot was warmed to 
37°C before fluxing. First, a baseline (120 s) level was recorded. Then, the tube 
was removed, 100 ng/ml hCCL2 was added and the tube was replaced. The 
experiment was recorded for an additional 120 s. We applied ionomycin stimu-
lation (1 µg/ml) as a positive control to verify equal dye loading.
The Ca2+ ratio (Fluo-4/Fura-Red) was measured over time using a 
FACSCanto (BD) and analyzed with FlowJo software. The results are ex-
pressed as percentages of normalized response, calculated as follows: ([median 
of Fluo-4/Fura-Red ratio]  [mean of the medians of Fluo-4/Fura-Red ratio 
before CCL2 addition])/([mean of the medians of Fluo-4/Fura-Red ratio 
during the response to ionomycin]  [mean of the medians of Fluo-4/ 
Fura-Red ratio before CCL2 addition]).
Enzymatic digestions. Human CXCL12, human CCL2, or mouse CCL2, 
untreated or RNS modified, were digested with trypsin (sequencing grade 
modified from Promega). Trypsin was added to the chemokines at an 
enzyme-to-substrate ratio of 1:50 (vol/vol) in 100 mM ammonium bicar-
bonate, pH 8.0, and incubated overnight at 37°C. The reaction was stopped 
by adjusting the pH to 2.0 with the addition of TFA. Peptide samples were 
purified and concentrated using PepClean C-18 (Thermo Fisher Scientific), 
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regions of interest (ROIs) of 157 × 157 pixels were randomly selected, and 
their immunoreactive areas for nitrotyrosines or CD3 were quantified.
Western blotting. MSC-2 cells were cultured for 4 d in the presence of 
either 100 ng/ml IL-4 or 25 ng/ml IFN-. The cells were then treated or not 
with 25 or 50 µM AT38 for 24 and 48 h. Whole-cell extracts were obtained 
from 2 × 105 cells. The cells were collected and rinsed once in PBS, and then 
immediately frozen in liquid nitrogen. The samples were dissolved in 15 µl 
Laemmli buffer and denatured for 10 min at 98°C. The samples were separated 
electrophoretically on a 12% SDS-PAGE gel and transferred onto an Immobi-
lon P membrane (Millipore). The immunoblots were probed with anti-ARG1 
(Santa Cruz Biotechnology, Inc.) or anti-NOS2 (Santa Cruz Biotechnology, 
Inc.) Abs. Secondary HRP-conjugated Abs were obtained from GE Healthcare. 
The immunoblots were analyzed by ECL (GE Healthcare).
Statistical analysis. Statistical analyses were performed using the following: 
Student’s unpaired two-tailed t test and ANOVA one-way test analysis with 
Tukey’s Multiple Comparisons Test. Data are representative of at least three 
different experiments. Values are expressed as the means ± SE. Kaplan-Maier 
plots and the Mantel-Haenszel test were used to compare the survival of mice, 
and all pairwise multiple comparisons were analyzed with the Holm-Sidak 
method. The overall significance level was set at 0.05.
Online supplemental material. Fig. S1 shows the fragmentation (MS/MS) 
spectra of nitrated and control peptides from mouse CCL2, human CCL2, 
and mouse CXCL12. Fig. S2 shows that N-CXCL12 is not chemotactic 
for human and mouse T cells. Fig. S3 shows qRT-PCR results from tumor 
tissue extracts, indicating that AT38 treatment does not induce de novo 
CCL2 synthesis. In Fig. S4, tumor growth curves of single mice treated 
with a combination of AT38 and OVA257-264-specific CTLs are shown. The 
Supplemental data describes the rationale behind the design and synthe-
sis of AT38. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20101956/DC1.
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